spacer
home > > winter 2020 > paving the way
PUBLICATIONS


Paving the Way



Over the last few decades, there have been more new drug launches than ever before, with a recordbreaking 59 approvals by the FDA in 2018 (1). This has, in part, been fueled by the shift to treatments customised for rare diseases and personalised medicines, which accounted for 42% of all approvals last year (2). The pace of innovation has accelerated as researchers and scientists challenge the frontiers of genomics, microbiology, and diagnostics, contributing to a dramatic rise in the number of trials demanded in the growing life science industry (3).

However, while breakthroughs continue to be made, the path to bring new medicines to market has not shortened. In fact, the drug development process has become increasingly complex, and the pace of trials is slow (4). Finding targeted patient populations and investigators to participate in trials is difficult as sponsor companies compete to collect more and more clinical research data, much of which is difficult and time-consuming to measure (5).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Rik Van Mol is Vice President, Cloud Strategy, at Veeva Systems with over 20 years of experience in both management consulting and cloud software in the life science/pharma sector. Rik’s experience has been built in assisting clients through complex transformation programmes across the life sciences value chain for most of the world’s largest companies. Rik is a recognised thought leader in the industry with deep expertise in architecting, launching, and implementing innovative and industryleading strategies and solutions.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

Keele, UK and Matfors, Sweden, 30 March 2020: Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet (KI), one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego AB and Giessen University.
More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

 
Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement